Pharmacist responsiveness and readiness for oral antivirals for COVID-19: A rebuttal to the AMA statement regarding the Biden administration’s test-to-treat plan

Hughes, David; Mordino, Jason

doi:10.1016/j.japh.2022.03.023

Cited by 5 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Community pharmacists are trusted HCPs and readily accessible to patients [ 23 , 24 ]. Management of both testing and treatment of high-risk patients by pharmacists as a single point of care could be a potential strategy for reducing barriers to accessing antiviral therapies for COVID-19 during times of increased need in the community and pressure on healthcare systems [ 23 ].…”

Section: Resultsmentioning

confidence: 99%

The Management of Patients at High Risk of Serious COVID-19 Disease: Optimising the Patient Pathway in the Middle East, Africa, and Eastern Europe

Al-Salman,

Amir,

Moore

et al. 2024

Cureus

View full text Add to dashboard Cite

Introduction For patients at high risk of severe COVID-19 disease, antiviral therapeutic options are available to reduce the risk of hospitalization or death. Although many countries have developed national guidelines for COVID-19 management that include use of antiviral agents, it is unclear how these guidelines are used in daily clinical practice. This study aims to assess the management of high-risk COVID-19 patients in the Middle East, Africa, and Eastern Europe, with a focus on understanding current practices, challenges, and potential strategies for improvement. Methods Healthcare professionals (HCPs) from the Middle East, Africa, and Eastern Europe came together at a regional summit in February 2023 to share perspectives on the therapeutic management of patients at high risk of serious COVID-19 disease in the community. Summit participants represented diverse medical specialties, geographical regions, and healthcare settings. Key insights gathered during the summit were supplemented with evidence from the published literature via a non-systematic literature search of MEDLINE and online sources such as government reports since the start of 2020 to identify articles on disease burden, unmet needs, treatment access, antiviral therapy, guidelines related to individuals with COVID-19 at high-risk for poor outcomes in low- and middle-income countries (LMICs). Together, these sources were used by the authors to generate their recommendations for future priorities and optimal care pathways globally. Results Specific insights gathered from the summit were that participants reported that primary care is the first point of contact for high-risk patients, but the role of primary care physicians (PCPs) in treatment is uncertain. Additionally, participants highlighted that between-country differences in the care pathway for high-risk patients are due to variations in local treatment practices, healthcare system structures, and resourcing. In line with the published literature, participants agreed that HCP education is needed to support the identification, counseling, and appropriate management of high-risk patients and that pharmacists have a critical role to play in identifying clinically important potential interactions with antiviral treatment and recommending appropriate adjustments. Furthermore, patient hesitancy can result in late presentation, delayed treatment, and potential progression of symptoms. HCPs should proactively counsel high-risk patients, so they are aware of their risk and its implications and understand what to do if they experience symptoms of COVID-19. Targeted educational initiatives for patients are needed to mitigate reluctance to undergo COVID-19 testing and counter COVID-19 misinformation. Conclusion Collaboration among stakeholders is essential to optimize COVID-19 management for high-risk patients globally, ensuring effective implementation of guidelines and improving outcomes.

show abstract

Section: Resultsmentioning

confidence: 99%

The Management of Patients at High Risk of Serious COVID-19 Disease: Optimising the Patient Pathway in the Middle East, Africa, and Eastern Europe

Al-Salman,

Amir,

Moore

et al. 2024

Cureus

View full text Add to dashboard Cite

show abstract

“… 11 More recently, with clinical knowledge of oral antiviral therapies for COVID-19, pharmacists have become experts in management of a new complex disease. 12 …”

mentioning

confidence: 99%

Pharmacist-Led Education for Increasing Physician Comfort Prescribing Oral COVID-19 Antivirals

Coulter¹,

Campbell²,

Ilges³

et al. 2023

The American Journal of Medicine

View full text Add to dashboard Cite

“…Pharmacists have been challenged with similar barriers in caring for patients with other disease states and have proven themselves to be an active part of healthcare teams to overcome these barriers. 3 , 4 As a result of the increasing number of available COVID-19 therapies along with a surge in COVID-19 cases, the pharmacy department at Boston Medical Center (BMC) recognized the need to implement a novel multidisciplinary system to rapidly increase appropriate prescribing of, safe dispensing of, and adequate access to these advanced therapies. This article provides an outline of the processes our institution put in place to organize a multidisciplinary approach to improving COVID-19–related patient care and lessons learned to aid other institutions in organizing similar efforts.…”

mentioning

confidence: 99%

Pharmacist-driven assessment and prescribing of COVID-19 therapeutics: A large, tertiary academic medical center’s experience

Famularo

Koloski

Marathe

et al. 2022

American Journal of Health-System Pharmacy

Self Cite

View full text Add to dashboard Cite

Disclaimer In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.

show abstract

Pharmacist responsiveness and readiness for oral antivirals for COVID-19: A rebuttal to the AMA statement regarding the Biden administration’s test-to-treat plan

Cited by 5 publications

References 5 publications

The Management of Patients at High Risk of Serious COVID-19 Disease: Optimising the Patient Pathway in the Middle East, Africa, and Eastern Europe

The Management of Patients at High Risk of Serious COVID-19 Disease: Optimising the Patient Pathway in the Middle East, Africa, and Eastern Europe

Pharmacist-Led Education for Increasing Physician Comfort Prescribing Oral COVID-19 Antivirals

Pharmacist-driven assessment and prescribing of COVID-19 therapeutics: A large, tertiary academic medical center’s experience

Contact Info

Product

Resources

About